HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf To Enter US Sun Care With Curiously Timed Coppertone Acquisition

Executive Summary

The Germany-based skin-care specialist will pay Bayer $550m for the iconic brand and gain entry to the US sunscreen market. The US represents the world’s biggest opportunity for sun care, but it’s also rife with uncertainty following FDA’s recent call for data to support key active ingredients’ continued GRASE status.

You may also be interested in...



Bayer Trims Consumer Portfolio Selling Solarcaine, Other US, Canada Skin Care Brands To WellSpring

WellSpring, owned by private equity firm Avista Capital Partners, purchasing Solarcaine, diaper rash and skin protectant A+D and Canadian brands Cortate and Complex 15. Bayer’s long-term commitment to consumer health one of key issues facing its next CEO, Bill Anderson.

L’Oréal Plans Largest Deal: $2.52Bn For Aesop

L’Oréal plans to acquire Australian luxury beauty brand Aesop from Natura & Co. in third quarter, subject to regulatory approvals, marking its biggest acquisition to date.

US Demand For Eucerin Drives Beiersdorf To Spread Brand Into Sun Care, Post-Acne

Beiersdorf extends Eucerin line combining skin treatment with sun care and moves the brand into post-acne category using Thiamidol ingredient. Eucerin and Aquaphor brand sales grew 18.2% in its latest quarter.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel